<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886821</url>
  </required_header>
  <id_info>
    <org_study_id>B1111001</org_study_id>
    <secondary_id>CVX-096-101</secondary_id>
    <nct_id>NCT00886821</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics</brief_title>
  <official_title>A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2
      diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04856883 on Day 1</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1</time_frame>
    <description>AUClast was defined as area under the concentration-time curve from time zero to the time of last measured concentration and calculated by using linear up/log down trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 1</measure>
    <time_frame>Cohort 1-9: pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1; Cohort 10-12: pre-dose, 1 and 6 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 8</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 22</measure>
    <time_frame>pre-dose, 1 and 6 hours post-dose on Day 22</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 1</measure>
    <time_frame>Cohort 1-9: pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1; Cohort 10-12: pre-dose, 1 and 6 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 8</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 22</measure>
    <time_frame>pre-dose, 1 and 6 hours post-dose on Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 1</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1</time_frame>
    <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Apparent Terminal Half-Life (t1/2) of PF-04856883 on Day 8</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 8</time_frame>
    <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 22</measure>
    <time_frame>pre-dose, 1 and 6 hours post-dose on Day 22</time_frame>
    <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Mean Residence Time (MRT) of PF-04856883 on Day 1</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose Day 1</time_frame>
    <description>MRT is defined as AUMC(0 - inf) divided by AUC(0 - inf), where AUMC(0 - inf) is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method and AUC(0 - inf) is the area under the concentration-time curve extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Apparent Oral Clearance (CL/F) of PF-04856883 on Day 1</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose Day 1</time_frame>
    <description>Apparent oral clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug apparent oral clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0 - Inf]) of PF-04856883 on Day 1</measure>
    <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose Day 1</time_frame>
    <description>AUC(0 - inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It was calculated as AUC (0-t) plus (last measurable concentration divided by apparent terminal elimination rate constant).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Cohort 1-8: Baseline up to Day 29; Cohort 9: Baseline up to Day 36; Cohort 10-12: Baseline up to Day 50</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stage 1: Change From Baseline in Post-Prandial Area Under the Curve (AUC) of Glucose at Day 3 and 7</measure>
    <time_frame>Baseline, Day 3 and 7</time_frame>
    <description>Area under the glucose concentration-time curve from 0 minute (approximately 20 minutes prior to the meal) to 180 minutes post initiation of meal.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stage 1: Change From Baseline in 7-point Weighted Mean Glucose at Day 3 and Day 7</measure>
    <time_frame>Baseline, Day 3 and 7</time_frame>
    <description>It was assessed by 7-point glucose measurements via the glucose oxidase method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
    <description>Criteria for laboratory abnormalities: Hemoglobin (Hgb), hematocrit: less than (&lt;) 0.8*lower limit of normal (LLN), platelet: &lt;75 or greater than (&gt;) 700*10^3/millimeter (mm)^3*upper limit of normal (ULN), leukocyte: &lt;2.5 or &gt;17.5*10^3/mm^3*ULN; total bilirubin 1.5*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase: &gt;3.0*ULN, total protein, albumin: &lt;0.8*LLN or &gt;1.2*ULN ;blood urea nitrogen, creatinine: &gt;1.3*ULN, uric acid &gt;1.2*ULN; sodium &lt;0.95*LLN or &gt;1.05*ULN, potassium, calcium: &lt;0.9*LLN or &gt;1.1*ULN, albumin, total protein &lt;0.8*LLN or &gt;1.2*ULN; glucose &lt;0.6*LLN or &gt;1.5*ULN, creatine kinase &gt;2.0*ULN; urine (red blood cell, white blood cell &gt;6/high power field).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Clinically Significant Vital Signs</measure>
    <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
    <description>Criteria for vital signs: pulse rate &lt;40 beats per minute (bpm), supine, sitting and erect pulse rate &lt;40 bpm, supine pulse rate &gt;120 bpm, sitting pulse rate &gt;120 bpm, and erect pulse rate &gt;120 bpm; systolic blood pressure: SBP &lt;90 millimeters of mercury (mmHg), change from baseline in SBP greater than or equal to (&gt;=) 30 mmHg; diastolic blood pressure: DBP &lt;50 mmHg, change from baseline in DBP &gt;=20 mmHg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings</measure>
    <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
    <description>Criteria for ECG findings: PR interval &gt;=300 millisecond (msec), &gt;=25 percent increase when baseline &gt;200 msec, and &gt;=50 percent increase when baseline less than or equal to (&lt;=) 200 msec; QRS interval &gt;=200 msec, &gt;=25 percent increase when baseline &gt;=100 msec, and &gt;=50 percent increase when baseline &lt;=100 msec; QT/QTc interval (corrected QT interval) &gt;=500 msec.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examinations</measure>
    <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
    <description>Full physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any clinically significant changes in physical status, as determined by the investigator.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stage 1: Number of Participants With Hypoglycemia</measure>
    <time_frame>Day 1: 0 hour (pre-dose) up to 48 hours post dose</time_frame>
    <description>Blood glucose level was checked for hypoglycemia by glucometer. Criteria for hypoglycemia: blood glucose level &lt;60 mg/dL if accompanied by symptoms, blood glucose level &lt;=50 mg/dL regardless of symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stage 1: Number of Participants With Clinically Significant Abnormal Rhythms</measure>
    <time_frame>Cohort 1- 8: Day 1 up to Day 3; Cohort 9: Day 1 up to Day 10</time_frame>
    <description>Criteria for abnormal rhythms: asymptomatic marked sinus bradycardia rate &lt;35 bpm; asymptomatic supraventricular couplets, atrial bigeminy lasting &gt;30 seconds; asymptomatic ventricular couplets, ventricular bigeminy lasting &gt;30 seconds; asymptomatic type I second degree (wenckebach) atrioventricular block of &gt;30 seconds duration; asymptomatic frequent premature ventricular complexes (=&gt;200/24 hours); asymptomatic frequent premature atrial complexes (=&gt;240/24 hours).</description>
  </other_outcome>
  <other_outcome>
    <measure>Stage 1: Number of Participants With Anti-Drug Antibodies</measure>
    <time_frame>Day 0, 8, 14, 15, 21, 28 and 35</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stage 2: Number of Participants With Anti-Drug Antibodies</measure>
    <time_frame>Day 0, 29 and 50</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CVX-096</intervention_name>
    <description>Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and/or female patients (females will be women of non-childbearing potential) with
             an historical diagnosis of type 2 diabetes mellitus, who are currently being treated
             with metformin at a dose at or near maximum.

          -  Hb A1c between 7-10%.

          -  Fasting C-peptide &gt;0.4 nmol/L.

        Exclusion Criteria:

          -  History of clinically significant chronic conditions other than T2DM not well
             controlled by either diet or medications.

          -  Patients with pancreatitis or considered a high risk for pancreatitis.

          -  History of contraindications to metformin therapy.

          -  Previous treatment with an approved or investigational GLP 1 mimetic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1111001&amp;StudyName=A%20Safety%20and%20Pharmacokinetic%20Study%20of%20CVX-096%20in%20Type%202%20Diabetics%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <results_first_submitted>March 2, 2017</results_first_submitted>
  <results_first_submitted_qc>March 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2017</results_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1 Type 2 diabetes CVX-096 diabetes mellitus</keyword>
  <keyword>adult-onset diabetes mellitus</keyword>
  <keyword>non-insulin dependent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study consist of two stages: stage 1 and stage 2. Participants were enrolled and randomized for stage 1 and stage 2 separately.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
          <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: PF-04856883 0.3 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: PF-04856883 1.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4: PF-04856883 3.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5: PF-04856883 6.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6: PF-04856883 12.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7: PF-04856883 24.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 8: PF-04856883 36.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 9: PF-04856883 18.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 1-9: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
        </group>
        <group group_id="P11">
          <title>Cohort 10: PF-04856883 15.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="P12">
          <title>Cohort 11: PF-04856883 20.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="P13">
          <title>Cohort 12: PF-04856883 25.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="P14">
          <title>Cohort 10-12: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="9"/>
                <participants group_id="P13" count="13"/>
                <participants group_id="P14" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
          <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: PF-04856883 0.3 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: PF-04856883 1.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4: PF-04856883 3.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5: PF-04856883 6.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 6: PF-04856883 12.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 7: PF-04856883 24.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 8: PF-04856883 36.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 9: PF-04856883 18.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 9: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or two dose on Day 1 and 8 respectively.</description>
        </group>
        <group group_id="B11">
          <title>Cohort 10: PF-04856883 15.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="B12">
          <title>Cohort 11: PF-04856883 20.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="B13">
          <title>Cohort 12: PF-04856883 25.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="B14">
          <title>Cohort 10-12: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="18"/>
            <count group_id="B11" value="9"/>
            <count group_id="B12" value="9"/>
            <count group_id="B13" value="13"/>
            <count group_id="B14" value="9"/>
            <count group_id="B15" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="13"/>
                    <measurement group_id="B14" value="8"/>
                    <measurement group_id="B15" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stage 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04856883 on Day 1</title>
        <description>AUClast was defined as area under the concentration-time curve from time zero to the time of last measured concentration and calculated by using linear up/log down trapezoidal method.</description>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1</time_frame>
        <population>Pharmacokinetic (PK) analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. 'N'(Overall number of participants)=participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort(Cohort 9),as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04856883 on Day 1</title>
          <description>AUClast was defined as area under the concentration-time curve from time zero to the time of last measured concentration and calculated by using linear up/log down trapezoidal method.</description>
          <population>Pharmacokinetic (PK) analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. 'N'(Overall number of participants)=participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort(Cohort 9),as pre-specified in protocol.</population>
          <units>nanogram*hour per milliliter (ng*hr)/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="865" spread="625.3"/>
                    <measurement group_id="O2" value="4960" spread="462.0"/>
                    <measurement group_id="O3" value="7065" spread="192.1"/>
                    <measurement group_id="O4" value="32552" spread="127.7"/>
                    <measurement group_id="O5" value="105950" spread="53.4"/>
                    <measurement group_id="O6" value="304167" spread="25.9"/>
                    <measurement group_id="O7" value="120521" spread="5404.6"/>
                    <measurement group_id="O8" value="297503" spread="211.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 1</title>
        <time_frame>Cohort 1-9: pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1; Cohort 10-12: pre-dose, 1 and 6 hours post-dose on Day 1</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 1</title>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" lower_limit="144" upper_limit="168"/>
                    <measurement group_id="O2" value="72.1" lower_limit="36.0" upper_limit="144"/>
                    <measurement group_id="O3" value="168" lower_limit="96.0" upper_limit="168"/>
                    <measurement group_id="O4" value="72.0" lower_limit="48.0" upper_limit="168"/>
                    <measurement group_id="O5" value="144" lower_limit="72.0" upper_limit="168"/>
                    <measurement group_id="O6" value="120" lower_limit="72.0" upper_limit="168"/>
                    <measurement group_id="O7" value="108" lower_limit="36.0" upper_limit="168"/>
                    <measurement group_id="O8" value="96.0" lower_limit="48.0" upper_limit="168"/>
                    <measurement group_id="O9" value="84.0" lower_limit="36.0" upper_limit="144"/>
                    <measurement group_id="O10" value="168" lower_limit="48.0" upper_limit="168"/>
                    <measurement group_id="O11" value="168" lower_limit="48.0" upper_limit="168"/>
                    <measurement group_id="O12" value="168" lower_limit="25.1" upper_limit="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 8</title>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 8</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. The outcome was not planned to be analyzed for single dosing cohorts (Cohort 1 to 8), since the dosing was done only on Day 1 in these cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 8</title>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. The outcome was not planned to be analyzed for single dosing cohorts (Cohort 1 to 8), since the dosing was done only on Day 1 in these cohorts.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="48.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 22</title>
        <time_frame>pre-dose, 1 and 6 hours post-dose on Day 22</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04856883 on Day 22</title>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="6.00" upper_limit="168"/>
                    <measurement group_id="O2" value="46.9" lower_limit="1.00" upper_limit="48.0"/>
                    <measurement group_id="O3" value="48.0" lower_limit="47.2" upper_limit="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 1</title>
        <time_frame>Cohort 1-9: pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1; Cohort 10-12: pre-dose, 1 and 6 hours post-dose on Day 1</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 1</title>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" spread="104.9"/>
                    <measurement group_id="O2" value="29.0" spread="126.3"/>
                    <measurement group_id="O3" value="24.8" spread="92.3"/>
                    <measurement group_id="O4" value="149" spread="63.2"/>
                    <measurement group_id="O5" value="387" spread="52.4"/>
                    <measurement group_id="O6" value="900" spread="36.2"/>
                    <measurement group_id="O7" value="579" spread="1314.6"/>
                    <measurement group_id="O8" value="1299" spread="104.3"/>
                    <measurement group_id="O9" value="1082" spread="50.0"/>
                    <measurement group_id="O10" value="736" spread="47.1"/>
                    <measurement group_id="O11" value="1554" spread="38.3"/>
                    <measurement group_id="O12" value="958" spread="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage 1: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 8</title>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 8</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. The outcome was not planned to be analyzed for single dosing cohorts (Cohort 1 to 8), since the dosing was done only on Day 1 in these cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 8</title>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. The outcome was not planned to be analyzed for single dosing cohorts (Cohort 1 to 8), since the dosing was done only on Day 1 in these cohorts.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1536" spread="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stage 2: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 22</title>
        <time_frame>pre-dose, 1 and 6 hours post-dose on Day 22</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Maximum Observed Plasma Concentration (Cmax) of PF-04856883 on Day 22</title>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1767" spread="37.6"/>
                    <measurement group_id="O2" value="2193" spread="36.9"/>
                    <measurement group_id="O3" value="2253" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 1: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 1</title>
        <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 1</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 1</title>
          <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not estimable since PK concentration was below the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="188" spread="42.6"/>
                    <measurement group_id="O3" value="151" spread="5.14"/>
                    <measurement group_id="O4" value="186" spread="53.3"/>
                    <measurement group_id="O5" value="144" spread="12.0"/>
                    <measurement group_id="O6" value="163" spread="52.0"/>
                    <measurement group_id="O7" value="156" spread="45.6"/>
                    <measurement group_id="O8" value="159" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 1: Apparent Terminal Half-Life (t1/2) of PF-04856883 on Day 8</title>
        <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose on Day 8</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. The outcome was not planned to be analyzed for single dosing cohorts (Cohort 1 to 8), since the dosing was done only on Day 1 in these cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Apparent Terminal Half-Life (t1/2) of PF-04856883 on Day 8</title>
          <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. The outcome was not planned to be analyzed for single dosing cohorts (Cohort 1 to 8), since the dosing was done only on Day 1 in these cohorts.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 2: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 22</title>
        <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
        <time_frame>pre-dose, 1 and 6 hours post-dose on Day 22</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Apparent Terminal Elimination Half-Life (t1/2) of PF-04856883 on Day 22</title>
          <description>Apparent terminal elimination half-life is the time measured for the plasma concentration of PF-04856883 to decrease by one-half of its initial concentration.</description>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" spread="32.7"/>
                    <measurement group_id="O2" value="102" spread="44.9"/>
                    <measurement group_id="O3" value="149" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 1: Mean Residence Time (MRT) of PF-04856883 on Day 1</title>
        <description>MRT is defined as AUMC(0 - inf) divided by AUC(0 - inf), where AUMC(0 - inf) is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method and AUC(0 - inf) is the area under the concentration-time curve extrapolated to infinity.</description>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose Day 1</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Mean Residence Time (MRT) of PF-04856883 on Day 1</title>
          <description>MRT is defined as AUMC(0 - inf) divided by AUC(0 - inf), where AUMC(0 - inf) is the area under the first moment curve from time 0 extrapolated to infinite time, calculated using the linear/log trapezoidal method and AUC(0 - inf) is the area under the concentration-time curve extrapolated to infinity.</description>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not estimable since PK concentration was below the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="310" spread="69.4" lower_limit="205" upper_limit="373"/>
                    <measurement group_id="O3" value="316" spread="20.3" lower_limit="286" upper_limit="325"/>
                    <measurement group_id="O4" value="350" spread="70.5" lower_limit="227" upper_limit="399"/>
                    <measurement group_id="O5" value="281" spread="31.6" lower_limit="217" upper_limit="295"/>
                    <measurement group_id="O6" value="319" spread="77.8" lower_limit="176" upper_limit="390"/>
                    <measurement group_id="O7" value="239" spread="89.7" lower_limit="189" upper_limit="414"/>
                    <measurement group_id="O8" value="312" spread="70.7" lower_limit="216" upper_limit="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 1: Apparent Oral Clearance (CL/F) of PF-04856883 on Day 1</title>
        <description>Apparent oral clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug apparent oral clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose Day 1</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Apparent Oral Clearance (CL/F) of PF-04856883 on Day 1</title>
          <description>Apparent oral clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug apparent oral clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
          <units>Liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not estimable since PK concentration was below the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="0.0176" spread="20.4"/>
                    <measurement group_id="O3" value="0.0643" spread="27.4"/>
                    <measurement group_id="O4" value="0.0562" spread="36.5"/>
                    <measurement group_id="O5" value="0.0487" spread="53.5"/>
                    <measurement group_id="O6" value="0.0354" spread="25.6"/>
                    <measurement group_id="O7" value="0.0530" spread="47.5"/>
                    <measurement group_id="O8" value="0.0527" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stage 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0 - Inf]) of PF-04856883 on Day 1</title>
        <description>AUC(0 - inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It was calculated as AUC (0-t) plus (last measurable concentration divided by apparent terminal elimination rate constant).</description>
        <time_frame>pre-dose, 1, 6, 18, 24, 36, 48, 72, 96, 144, and 168 hours post-dose Day 1</time_frame>
        <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC[0 - Inf]) of PF-04856883 on Day 1</title>
          <description>AUC(0 - inf) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It was calculated as AUC (0-t) plus (last measurable concentration divided by apparent terminal elimination rate constant).</description>
          <population>PK analysis population included all randomized participants who received at least 1 dose of PF-04856883 and had PK data. Here, 'N' signifies those participants who were evaluable for this outcome measure. This outcome measure was not planned to be analyzed in multiple dosing cohort (Cohort 9), as pre specified in protocol.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was not estimable since PK concentration was below the lower limit of quantification.</measurement>
                    <measurement group_id="O2" value="17013" spread="20.4"/>
                    <measurement group_id="O3" value="15550" spread="27.4"/>
                    <measurement group_id="O4" value="53420" spread="36.5"/>
                    <measurement group_id="O5" value="123081" spread="53.5"/>
                    <measurement group_id="O6" value="339062" spread="25.6"/>
                    <measurement group_id="O7" value="452842" spread="47.5"/>
                    <measurement group_id="O8" value="682543" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>Cohort 1-8: Baseline up to Day 29; Cohort 9: Baseline up to Day 36; Cohort 10-12: Baseline up to Day 50</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O13">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O14">
            <title>Cohort 10-12: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="9"/>
                <count group_id="O13" value="13"/>
                <count group_id="O14" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="7"/>
                    <measurement group_id="O13" value="8"/>
                    <measurement group_id="O14" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stage 1: Change From Baseline in Post-Prandial Area Under the Curve (AUC) of Glucose at Day 3 and 7</title>
        <description>Area under the glucose concentration-time curve from 0 minute (approximately 20 minutes prior to the meal) to 180 minutes post initiation of meal.</description>
        <time_frame>Baseline, Day 3 and 7</time_frame>
        <population>Pharmacodynamic analysis population included all randomized participants who had received at least 1 dose of study medication and had PD data. Here, number analyzed signifies those participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Change From Baseline in Post-Prandial Area Under the Curve (AUC) of Glucose at Day 3 and 7</title>
          <description>Area under the glucose concentration-time curve from 0 minute (approximately 20 minutes prior to the meal) to 180 minutes post initiation of meal.</description>
          <population>Pharmacodynamic analysis population included all randomized participants who had received at least 1 dose of study medication and had PD data. Here, number analyzed signifies those participants who were evaluable at specified time points.</population>
          <units>milligram*hour per deciliter (mg*hr)/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="15"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="102"/>
                    <measurement group_id="O2" value="44.9" spread="76.8"/>
                    <measurement group_id="O3" value="-92.3" spread="78.2"/>
                    <measurement group_id="O4" value="-54.0" spread="60.0"/>
                    <measurement group_id="O5" value="46.7" spread="70.9"/>
                    <measurement group_id="O6" value="-74.5" spread="59.7"/>
                    <measurement group_id="O7" value="-140" spread="124"/>
                    <measurement group_id="O8" value="-80.1" spread="70.6"/>
                    <measurement group_id="O10" value="-10.6" spread="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="16"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.8" spread="95.5"/>
                    <measurement group_id="O2" value="29.3" spread="161"/>
                    <measurement group_id="O3" value="-147" spread="93.4"/>
                    <measurement group_id="O4" value="-23.0" spread="125"/>
                    <measurement group_id="O5" value="65.1" spread="85.1"/>
                    <measurement group_id="O6" value="-39.6" spread="52.6"/>
                    <measurement group_id="O7" value="-108" spread="139"/>
                    <measurement group_id="O8" value="-38.4" spread="66.7"/>
                    <measurement group_id="O9" value="-119" spread="81.7"/>
                    <measurement group_id="O10" value="-9.04" spread="119"/>
                    <measurement group_id="O11" value="-46.1" spread="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stage 1: Change From Baseline in 7-point Weighted Mean Glucose at Day 3 and Day 7</title>
        <description>It was assessed by 7-point glucose measurements via the glucose oxidase method.</description>
        <time_frame>Baseline, Day 3 and 7</time_frame>
        <population>Pharmacodynamic analysis population included all randomized participants who had received at least 1 dose of study medication and had PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Change From Baseline in 7-point Weighted Mean Glucose at Day 3 and Day 7</title>
          <description>It was assessed by 7-point glucose measurements via the glucose oxidase method.</description>
          <population>Pharmacodynamic analysis population included all randomized participants who had received at least 1 dose of study medication and had PD data.</population>
          <units>milligram per deciliter(mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="24.1"/>
                    <measurement group_id="O2" value="-0.0252" spread="16.3"/>
                    <measurement group_id="O3" value="-17.9" spread="21.7"/>
                    <measurement group_id="O4" value="1.04" spread="18.2"/>
                    <measurement group_id="O5" value="20.2" spread="18.4"/>
                    <measurement group_id="O6" value="-15.7" spread="12.4"/>
                    <measurement group_id="O7" value="-31.7" spread="30.5"/>
                    <measurement group_id="O8" value="-26.4" spread="22.9"/>
                    <measurement group_id="O9" value="-23.9" spread="10.6"/>
                    <measurement group_id="O10" value="0.506" spread="25.0"/>
                    <measurement group_id="O11" value="-16.6" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" spread="23.0"/>
                    <measurement group_id="O2" value="7.44" spread="42.1"/>
                    <measurement group_id="O3" value="-28.7" spread="26.9"/>
                    <measurement group_id="O4" value="-8.45" spread="33.6"/>
                    <measurement group_id="O5" value="7.05" spread="53.2"/>
                    <measurement group_id="O6" value="-20.5" spread="10.2"/>
                    <measurement group_id="O7" value="-33.9" spread="42.1"/>
                    <measurement group_id="O8" value="-24.4" spread="29.4"/>
                    <measurement group_id="O9" value="-12.8" spread="29.8"/>
                    <measurement group_id="O10" value="-5.22" spread="25.9"/>
                    <measurement group_id="O11" value="-23.0" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Clinically Significant Laboratory Abnormalities</title>
        <description>Criteria for laboratory abnormalities: Hemoglobin (Hgb), hematocrit: less than (&lt;) 0.8*lower limit of normal (LLN), platelet: &lt;75 or greater than (&gt;) 700*10^3/millimeter (mm)^3*upper limit of normal (ULN), leukocyte: &lt;2.5 or &gt;17.5*10^3/mm^3*ULN; total bilirubin 1.5*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase: &gt;3.0*ULN, total protein, albumin: &lt;0.8*LLN or &gt;1.2*ULN ;blood urea nitrogen, creatinine: &gt;1.3*ULN, uric acid &gt;1.2*ULN; sodium &lt;0.95*LLN or &gt;1.05*ULN, potassium, calcium: &lt;0.9*LLN or &gt;1.1*ULN, albumin, total protein &lt;0.8*LLN or &gt;1.2*ULN; glucose &lt;0.6*LLN or &gt;1.5*ULN, creatine kinase &gt;2.0*ULN; urine (red blood cell, white blood cell &gt;6/high power field).</description>
        <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O13">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O14">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O15">
            <title>Cohort 10-12: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Abnormalities</title>
          <description>Criteria for laboratory abnormalities: Hemoglobin (Hgb), hematocrit: less than (&lt;) 0.8*lower limit of normal (LLN), platelet: &lt;75 or greater than (&gt;) 700*10^3/millimeter (mm)^3*upper limit of normal (ULN), leukocyte: &lt;2.5 or &gt;17.5*10^3/mm^3*ULN; total bilirubin 1.5*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase: &gt;3.0*ULN, total protein, albumin: &lt;0.8*LLN or &gt;1.2*ULN ;blood urea nitrogen, creatinine: &gt;1.3*ULN, uric acid &gt;1.2*ULN; sodium &lt;0.95*LLN or &gt;1.05*ULN, potassium, calcium: &lt;0.9*LLN or &gt;1.1*ULN, albumin, total protein &lt;0.8*LLN or &gt;1.2*ULN; glucose &lt;0.6*LLN or &gt;1.5*ULN, creatine kinase &gt;2.0*ULN; urine (red blood cell, white blood cell &gt;6/high power field).</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="9"/>
                <count group_id="O13" value="9"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Clinically Significant Vital Signs</title>
        <description>Criteria for vital signs: pulse rate &lt;40 beats per minute (bpm), supine, sitting and erect pulse rate &lt;40 bpm, supine pulse rate &gt;120 bpm, sitting pulse rate &gt;120 bpm, and erect pulse rate &gt;120 bpm; systolic blood pressure: SBP &lt;90 millimeters of mercury (mmHg), change from baseline in SBP greater than or equal to (&gt;=) 30 mmHg; diastolic blood pressure: DBP &lt;50 mmHg, change from baseline in DBP &gt;=20 mmHg.</description>
        <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O13">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O14">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O15">
            <title>Cohort 10-12: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Vital Signs</title>
          <description>Criteria for vital signs: pulse rate &lt;40 beats per minute (bpm), supine, sitting and erect pulse rate &lt;40 bpm, supine pulse rate &gt;120 bpm, sitting pulse rate &gt;120 bpm, and erect pulse rate &gt;120 bpm; systolic blood pressure: SBP &lt;90 millimeters of mercury (mmHg), change from baseline in SBP greater than or equal to (&gt;=) 30 mmHg; diastolic blood pressure: DBP &lt;50 mmHg, change from baseline in DBP &gt;=20 mmHg.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="9"/>
                <count group_id="O13" value="9"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings</title>
        <description>Criteria for ECG findings: PR interval &gt;=300 millisecond (msec), &gt;=25 percent increase when baseline &gt;200 msec, and &gt;=50 percent increase when baseline less than or equal to (&lt;=) 200 msec; QRS interval &gt;=200 msec, &gt;=25 percent increase when baseline &gt;=100 msec, and &gt;=50 percent increase when baseline &lt;=100 msec; QT/QTc interval (corrected QT interval) &gt;=500 msec.</description>
        <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O13">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O14">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O15">
            <title>Cohort 10-12: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings</title>
          <description>Criteria for ECG findings: PR interval &gt;=300 millisecond (msec), &gt;=25 percent increase when baseline &gt;200 msec, and &gt;=50 percent increase when baseline less than or equal to (&lt;=) 200 msec; QRS interval &gt;=200 msec, &gt;=25 percent increase when baseline &gt;=100 msec, and &gt;=50 percent increase when baseline &lt;=100 msec; QT/QTc interval (corrected QT interval) &gt;=500 msec.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="9"/>
                <count group_id="O13" value="9"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Clinically Significant Physical Examinations</title>
        <description>Full physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any clinically significant changes in physical status, as determined by the investigator.</description>
        <time_frame>Cohort 1-8: Baseline up to Day 28; Cohort 9: Baseline up to Day 35; Cohort 10-12; Baseline up to Day 50</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O13">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O14">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O15">
            <title>Cohort 10-12: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examinations</title>
          <description>Full physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems. The examination assessed the participants for any clinically significant changes in physical status, as determined by the investigator.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
                <count group_id="O12" value="9"/>
                <count group_id="O13" value="9"/>
                <count group_id="O14" value="13"/>
                <count group_id="O15" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stage 1: Number of Participants With Hypoglycemia</title>
        <description>Blood glucose level was checked for hypoglycemia by glucometer. Criteria for hypoglycemia: blood glucose level &lt;60 mg/dL if accompanied by symptoms, blood glucose level &lt;=50 mg/dL regardless of symptoms.</description>
        <time_frame>Day 1: 0 hour (pre-dose) up to 48 hours post dose</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Number of Participants With Hypoglycemia</title>
          <description>Blood glucose level was checked for hypoglycemia by glucometer. Criteria for hypoglycemia: blood glucose level &lt;60 mg/dL if accompanied by symptoms, blood glucose level &lt;=50 mg/dL regardless of symptoms.</description>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stage 1: Number of Participants With Clinically Significant Abnormal Rhythms</title>
        <description>Criteria for abnormal rhythms: asymptomatic marked sinus bradycardia rate &lt;35 bpm; asymptomatic supraventricular couplets, atrial bigeminy lasting &gt;30 seconds; asymptomatic ventricular couplets, ventricular bigeminy lasting &gt;30 seconds; asymptomatic type I second degree (wenckebach) atrioventricular block of &gt;30 seconds duration; asymptomatic frequent premature ventricular complexes (=&gt;200/24 hours); asymptomatic frequent premature atrial complexes (=&gt;240/24 hours).</description>
        <time_frame>Cohort 1- 8: Day 1 up to Day 3; Cohort 9: Day 1 up to Day 10</time_frame>
        <population>Safety population will consist of all randomized patients who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Number of Participants With Clinically Significant Abnormal Rhythms</title>
          <description>Criteria for abnormal rhythms: asymptomatic marked sinus bradycardia rate &lt;35 bpm; asymptomatic supraventricular couplets, atrial bigeminy lasting &gt;30 seconds; asymptomatic ventricular couplets, ventricular bigeminy lasting &gt;30 seconds; asymptomatic type I second degree (wenckebach) atrioventricular block of &gt;30 seconds duration; asymptomatic frequent premature ventricular complexes (=&gt;200/24 hours); asymptomatic frequent premature atrial complexes (=&gt;240/24 hours).</description>
          <population>Safety population will consist of all randomized patients who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stage 1: Number of Participants With Anti-Drug Antibodies</title>
        <time_frame>Day 0, 8, 14, 15, 21, 28 and 35</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication. Here, number analyzed signifies those participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
            <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: PF-04856883 0.3 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: PF-04856883 1.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: PF-04856883 3.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: PF-04856883 6.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: PF-04856883 12.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7: PF-04856883 24.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 8: PF-04856883 36.0 mg</title>
            <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 9: PF-04856883 18.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 1-8: Combined Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 3, 7.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 9: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 1: Number of Participants With Anti-Drug Antibodies</title>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication. Here, number analyzed signifies those participants who were evaluable at specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="16"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="16"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="16"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="16"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="16"/>
                    <count group_id="O11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stage 2: Number of Participants With Anti-Drug Antibodies</title>
        <time_frame>Day 0, 29 and 50</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of study medication. Here, number analyzed signifies those participants who were evaluable at specified time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 10: PF-04856883 15.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 11: PF-04856883 20.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 12: PF-04856883 25.0 mg</title>
            <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 10-12: Placebo</title>
            <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
          </group>
        </group_list>
        <measure>
          <title>Stage 2: Number of Participants With Anti-Drug Antibodies</title>
          <population>Safety population included all randomized participants who received at least 1 dose of study medication. Here, number analyzed signifies those participants who were evaluable at specified time points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (n= 9, 9, 13 ,9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n= 9, 8, 7, 8)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (n= 9, 8, 8, 8)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: PF-04856883 0.1 Milligram (mg)</title>
          <description>Participants received single subcutaneous injection of PF-04856883 (CVX-096) 0.1 mg on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: PF-04856883 0.3 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 0.3 mg on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: PF-04856883 1.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 1.0 mg on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4: PF-04856883 3.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 3.0 mg on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5: PF-04856883 6.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 6.0 mg on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 6: PF-04856883 12.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 12.0 mg on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 7: PF-04856883 24.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 24.0 mg on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 8: PF-04856883 36.0 mg</title>
          <description>Participants received single subcutaneous injection of PF-04856883 36.0 mg on Day 1.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 9: PF-04856883 18.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 18.0 mg on Day 1 and 8.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 1-9: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection either single dose on Day 1 or multiple dose on Day 1 and 8 respectively.</description>
        </group>
        <group group_id="E11">
          <title>Cohort 10: PF-04856883 15.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 15.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="E12">
          <title>Cohort 11: PF-04856883 20.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 20.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="E13">
          <title>Cohort 12: PF-04856883 25.0 mg</title>
          <description>Participants received subcutaneous injection of PF-04856883 25.0 mg on Day 1, 8, 15 and 22.</description>
        </group>
        <group group_id="E14">
          <title>Cohort 10-12: Placebo</title>
          <description>Participants received placebo matched to PF-04856883 subcutaneous injection on Day 1, 8, 15 and 22.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pharyngeal hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Milia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

